# US 2021/0196813 A1 · Utilizing Vaccines to Treat Cancer and Enhance the Success Rate of Cancer Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196813 A1
- Document ID: US20210196813A1
- Status: Published application
- Kind: A1
- Application number: 17/134,663
- Filed: 2020-12-28
- Published: 2021-07-01
- Earliest claimed: 2019-12-27
- Assignees: Rush University Medical Center
- Applicants: Rush University Medical Center
- Inventors: Andrew ZLOZA; Jenna H. NEWMAN
- Web page: https://patentgrep.com/patent/US20210196813A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/812: {Breast}
- A61K 2039/876: {Skin, melanoma}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods treating cancer are provided. The methods include intratumorally administering a therapeutically effective dose of a vaccine to a subject in need thereof.

## Claims

### Claim 1

A method of treating of treating cancer comprising:
intratumorally administering a therapeutically effective dose of a vaccine to a subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the vaccine is a monovalent or a multivalent vaccine.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the vaccine is an influenza vaccine.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the influenza vaccine is a seasonal influenza vaccine.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the vaccine is selected from the group consisting of DTaP (diphtheria, pertussis and tetanus), Pneumovax (Pneumococcal Pneumonia), HepB (hepatitis B), and MMR (measles, mumps, rubella).

### Claim 6 (depends on 1)

The method according to claim 1, wherein the influenza vaccine is an FDA approved vaccine.

### Claim 7 (depends on 1)

The method according to claim 1, wherein multiple doses of the vaccine are administered.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the intratumoral administration is by injection or during a biopsy procedure.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the vaccine is inactivated.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the vaccine is unadjuvanted.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the cancer is selected from the group consisting of melanoma, non-small cell lung, small-cell lung, lung, hepatocarcinoma, retinoblastoma, astrocytoma, glioblastoma, leukemia, neuroblastoma, head, neck, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, urogenital, respiratory tract, hematopoietic, musculoskeletal, neuroendocrine, carcinoma, sarcoma, central nervous system, peripheral nervous system, lymphoma, brain, colon or bladder cancer.

### Claim 12 (depends on 1)

The method according to claim 1, further comprising administering at least one additional anticancer treatment.

### Claim 13 (depends on 12)

The method of claim 12, wherein the at least one additional anticancer treatment is surgical therapy, chemotherapy, radiation therapy, hormonal therapy, immunotherapy, small molecule therapy, receptor kinase inhibitor therapy, anti-angiogenic therapy, cytokine therapy, cryotherapy, radioablation or a biological therapy.

### Claim 14 (depends on 12)

The method of claim 12, wherein the at least one additional anticancer treatment is an immune checkpoint inhibitor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the at least one checkpoint inhibitor is selected from an inhibitor of Programmed T cell death 1 (PD-1), programmed T cell death ligand 1 (PD-L1), PDL-2, Cytotoxic T-lymphocyte antigen 4 (CTLA-4), Lymphocyte-activation gene 3 (LAG-3), Tim-3, CD28, CD122, or CD137.

### Claim 16 (depends on 15)

The method of claim 15, wherein the at least one checkpoint inhibitor is an anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CTLA4 antibody, or anti-LAG3 antibody.

### Claim 17 (depends on 16)

The method of claim 16, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-514, REGN2810, CT-011, BMS 936559, MPDL3280A and AMP-224, wherein the anti-PD-L1 antibody is selected from the group consisting of durvalumab, atezolizumab, and avelumab and wherein wherein the anti-CTLA-4 antibody is tremelimumab or ipilimumab.

### Claim 18 (depends on 14)

The method of claim 14, wherein more than one checkpoint inhibitor is administered.

### Claim 19

A method of increasing an immune response in a tumor, the method comprising:
intratumorally administering a therapeutically effective dose of an influenza vaccine to a subject in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the influenza vaccine is a non-B-cell promoting vaccine.
